BS_53M8PP88
Ependymoma NOS
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ependymoma NOS
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ependymoma NOS
- overall_survival_months
- 82.78580814717476
- age_years
- 3.351
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.546
- MYC_TARGETS_V2+0.526
- E2F_TARGETS+0.515
- DNA_REPAIR+0.451
- G2M_CHECKPOINT+0.425
- WNT_BETA_CATENIN_SIGNALING+0.418
- OXIDATIVE_PHOSPHORYLATION+0.334
- UNFOLDED_PROTEIN_RESPONSE+0.219
- SPERMATOGENESIS+0.206
- MITOTIC_SPINDLE+0.205
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.571
- IL6_JAK_STAT3_SIGNALING-0.558
- ALLOGRAFT_REJECTION-0.542
- INTERFERON_GAMMA_RESPONSE-0.538
- TNFA_SIGNALING_VIA_NFKB-0.514
- KRAS_SIGNALING_UP-0.505
- ANGIOGENESIS-0.472
- IL2_STAT5_SIGNALING-0.446
- INTERFERON_ALPHA_RESPONSE-0.427
- COMPLEMENT-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_53M8PP88 | EPN | EPN Tumor | 0.978 |
| 2 | BS_VJ2S5DVS | Ependymoma NOS | — | 0.917 |
| 3 | SJEPD030950_D1.RNA-Seq | EPN | EPN Tumor | 0.912 |
| 4 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.907 |
| 5 | TCGA-85-8352-01A-31R-2326-07 | — | cohortMD1 | 0.907 |
| 6 | SRR4195654 | — | — | 0.906 |
| 7 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.905 |
| 8 | SRR8613736 | — | E | 0.904 |
| 9 | ERR2208894 | — | — | 0.901 |
| 10 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.546 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.526 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.515 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.451 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.425 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.418 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.334 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.219 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.206 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.205 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.194 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.185 | Inavolisib | — uncovered |
| PEROXISOME | 0.182 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.063 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.047 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.016 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.015 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.002 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.002 | Idelalisib | — uncovered |